Conivaptan

This classification denotes a vasopressin antagonist with the molecular formula C32H26N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NJ98Y462X, chemically known as (1,1-biphenyl)-2-carboxamide, n-(4-(4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1h)-yl)carbonyl)phenyl)- but generally known as conivaptan, which bears US NIH Compound Identifier 151171. European Medicines Agency schedules Conivaptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32706. The term CONIVAPTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44). World Health Organization schedules conivaptan in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule conivaptan under HS 29339930 and SITC 51577. As of Q4 2014, CONIVAPTAN remains the US FDA Preferred Term for this commodity. Conivaptan bears US NLM identifiers UMLS ID C0966107 and NCI Concept Code C74428. SMILES: O=C(N1CCC2[NH]C(NC2C2C1CCCC2)C)C1CCC(NC(=O)C2C(C3CCCCC3)CCCC2)CC1.